Drug: 5 mg BGM0504 Administered SC

DRUG2 trials

Sponsors

BrightGene Bio-Medical Technology Co., Ltd.

Conditions

Type 2 Diabetes Mellitus (T2DM)

Phase 3

A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

RecruitingNCT06716203

BrightGene Bio-Medical Technology Co., Ltd.Type 2 Diabetes Mellitus (T2DM)

Start: 2024-12-02End: 2026-08-25Target: 207Updated: 2025-02-07

A Study of BGM0504 in Participants with Type 2 Diabetes

RecruitingNCT06716216

BrightGene Bio-Medical Technology Co., Ltd.Type 2 Diabetes Mellitus (T2DM)

Start: 2024-11-29End: 2026-11-14Target: 537Updated: 2025-02-07